{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:08:10Z","timestamp":1790208490057,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00345-021-03893-1","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T10:02:53Z","timestamp":1642586573000},"page":"79-86","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Active surveillance for intermediate-risk prostate cancer"],"prefix":"10.1007","volume":"40","author":[{"given":"Madhur","family":"Nayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe L. F.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2989-9091","authenticated-orcid":false,"given":"Adam S.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,19]]},"reference":[{"issue":"3","key":"3893_CR1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.juro.2017.11.095","volume":"199","author":"MG Sanda","year":"2018","unstructured":"Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV (2018) Clinically localized prostate cancer: AUA\/ASTRO\/SUO guideline. Part I: risk stratification, shared decision making, and care options. J Urol 199(3):683\u2013690","journal-title":"J Urol"},{"issue":"30","key":"3893_CR2","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1200\/JCO.2015.62.5764","volume":"33","author":"JJ Tosoian","year":"2015","unstructured":"Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, Carter HB (2015) Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol 33(30):3379\u20133385. https:\/\/doi.org\/10.1200\/JCO.2015.62.5764","journal-title":"J Clin Oncol"},{"issue":"15","key":"3893_CR3","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","volume":"375","author":"FC Hamdy","year":"2016","unstructured":"Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375(15):1415\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa1606220","journal-title":"N Engl J Med"},{"issue":"6","key":"3893_CR4","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.eururo.2020.02.009","volume":"77","author":"TJ Wilt","year":"2020","unstructured":"Wilt TJ, Vo TN, Langsetmo L, Dahm P, Wheeler T, Aronson WJ, Cooperberg MR, Taylor BC, Brawer MK (2020) Radical prostatectomy or observation for clinically localized prostate cancer: extended follow-up of the prostate cancer intervention versus observation trial (PIVOT). Eur Urol 77(6):713\u2013724. https:\/\/doi.org\/10.1016\/j.eururo.2020.02.009","journal-title":"Eur Urol"},{"issue":"1","key":"3893_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/JU.0000000000001241","volume":"205","author":"V Agrawal","year":"2021","unstructured":"Agrawal V, Ma X, Hu JC, Barbieri CE, Nagar H (2021) Active surveillance for men with intermediate risk prostate cancer. J Urol 205(1):115\u2013121","journal-title":"J Urol"},{"issue":"3","key":"3893_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/bju.14935","volume":"125","author":"L Klotz","year":"2020","unstructured":"Klotz L (2020) Active surveillance in intermediate-risk prostate cancer. BJU Int 125(3):346\u2013354","journal-title":"BJU Int"},{"issue":"6","key":"3893_CR7","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/MOU.0000000000000671","volume":"29","author":"MR Overland","year":"2019","unstructured":"Overland MR, Washington SL III, Carroll PR, Cooperberg MR, Herlemann A (2019) Active surveillance for intermediate-risk prostate cancer: yes, but for whom? Curr Opin Urol 29(6):605\u2013611","journal-title":"Curr Opin Urol"},{"issue":"6","key":"3893_CR8","doi-asserted-by":"publisher","first-page":"e739","DOI":"10.1016\/j.clgc.2020.05.008","volume":"18","author":"D Enikeev","year":"2020","unstructured":"Enikeev D, Morozov A, Taratkin M, Barret E, Kozlov V, Singla N, Rivas JG, Podoinitsin A, Margulis V, Glybochko P (2020) Active surveillance for intermediate-risk prostate cancer: systematic review and meta-analysis of current protocols and outcomes. Clin Genitourin Cancer 18(6):e739\u2013e753. https:\/\/doi.org\/10.1016\/j.clgc.2020.05.008","journal-title":"Clin Genitourin Cancer"},{"issue":"12","key":"3893_CR9","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/jnci\/djp122","volume":"101","author":"MR Cooperberg","year":"2009","unstructured":"Cooperberg MR, Broering JM, Carroll PR (2009) Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 101(12):878\u2013887. https:\/\/doi.org\/10.1093\/jnci\/djp122","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"3893_CR10","doi-asserted-by":"publisher","first-page":"e259","DOI":"10.1016\/s1470-2045(12)70084-0","volume":"13","author":"ZS Zumsteg","year":"2012","unstructured":"Zumsteg ZS, Zelefsky MJ (2012) Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care? Lancet Oncol 13(6):e259-269. https:\/\/doi.org\/10.1016\/s1470-2045(12)70084-0","journal-title":"Lancet Oncol"},{"issue":"3","key":"3893_CR11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ijrobp.2012.06.030","volume":"85","author":"KO Castle","year":"2013","unstructured":"Castle KO, Hoffman KE, Levy LB, Lee AK, Choi S, Nguyen QN, Frank SJ, Pugh TJ, McGuire SE, Kuban DA (2013) Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int J Radiat Oncol Biol Phys 85(3):693\u2013699. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.06.030","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"24","key":"3893_CR12","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1056\/NEJMoa1807801","volume":"379","author":"A Bill-Axelson","year":"2018","unstructured":"Bill-Axelson A, Holmberg L, Garmo H, Taari K, Busch C, Nordling S, H\u00e4ggman M, Andersson SO, Andr\u00e9n O, Steineck G, Adami HO, Johansson JE (2018) Radical prostatectomy or watchful waiting in prostate cancer - 29-year follow-up. N Engl J Med 379(24):2319\u20132329. https:\/\/doi.org\/10.1056\/NEJMoa1807801","journal-title":"N Engl J Med"},{"issue":"4","key":"3893_CR13","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/bju.14987","volume":"125","author":"RJ Bryant","year":"2020","unstructured":"Bryant RJ, Oxley J, Young GJ, Lane JA, Metcalfe C, Davis M, Turner EL, Martin RM, Goepel JR, Varma M, Griffiths DF, Grigor K, Mayer N, Warren AY, Bhattarai S, Dormer J, Mason M, Staffurth J, Walsh E, Rosario DJ, Catto JWF, Neal DE, Donovan JL, Hamdy FC (2020) The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. BJU Int 125(4):506\u2013514. https:\/\/doi.org\/10.1111\/bju.14987","journal-title":"BJU Int"},{"key":"3893_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.09.042","author":"N Mottet","year":"2020","unstructured":"Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, van der Kwast TH, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, van der Poel HG, Rouvi\u00e8re O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Cornford P (2020) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.042","journal-title":"Eur Urol"},{"issue":"2","key":"3893_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.euf.2020.01.001","volume":"7","author":"P Rajwa","year":"2021","unstructured":"Rajwa P, Sprenkle PC, Leapman MS (2021) When and how should active surveillance for prostate cancer be de-escalated? Eur Urol Focus 7(2):297\u2013300. https:\/\/doi.org\/10.1016\/j.euf.2020.01.001","journal-title":"Eur Urol Focus"},{"issue":"9","key":"3893_CR16","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/pros.23352","volume":"77","author":"TM de Carvalho","year":"2017","unstructured":"de Carvalho TM, Heijnsdijk EAM, de Koning HJ (2017) When should active surveillance for prostate cancer stop if no progression is detected? Prostate 77(9):962\u2013969. https:\/\/doi.org\/10.1002\/pros.23352","journal-title":"Prostate"},{"key":"3893_CR17","first-page":"605","volume-title":"Urologic oncology: seminars and original investigations","author":"R Savdie","year":"2017","unstructured":"Savdie R, Aning J, So AI, Black PC, Gleave ME, Goldenberg SL (2017) Identifying intermediate-risk candidates for active surveillance of prostate cancer. Urologic oncology: seminars and original investigations, vol 10. Elsevier, p 605"},{"issue":"6","key":"3893_CR18","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.juro.2016.06.102","volume":"196","author":"HB Musunuru","year":"2016","unstructured":"Musunuru HB, Yamamoto T, Klotz L, Ghanem G, Mamedov A, Sethukavalan P, Jethava V, Jain S, Zhang L, Vesprini D (2016) Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunnybrook experience. J Urol 196(6):1651\u20131658","journal-title":"J Urol"},{"issue":"1","key":"3893_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/21681805.2017.1380697","volume":"52","author":"M Thostrup","year":"2018","unstructured":"Thostrup M, Thomsen FB, Iversen P, Brasso K (2018) Active surveillance for localized prostate cancer: update of a prospective single-center cohort. Scan J Urol 52(1):14\u201319","journal-title":"Scan J Urol"},{"issue":"8","key":"3893_CR20","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1097\/pas.0000000000000235","volume":"38","author":"CC Huang","year":"2014","unstructured":"Huang CC, Kong MX, Zhou M, Rosenkrantz AB, Taneja SS, Melamed J, Deng FM (2014) Gleason score 3 + 4=7 prostate cancer with minimal quantity of gleason pattern 4 on needle biopsy is associated with low-risk tumor in radical prostatectomy specimen. Am J Surg Pathol 38(8):1096\u20131101. https:\/\/doi.org\/10.1097\/pas.0000000000000235","journal-title":"Am J Surg Pathol"},{"key":"3893_CR21","doi-asserted-by":"publisher","first-page":"117955571774013","DOI":"10.1177\/1179555717740130","volume":"10","author":"PLSJ Us\u00f3n","year":"2017","unstructured":"Us\u00f3n PLSJ, Macarenco RSES, Oliveira FN, Smaletz O (2017) Impact of pathology review for decision therapy in localized prostate cancer. Clin Med Insights Pathol 10:1179555717740130\u20131179555717740130. https:\/\/doi.org\/10.1177\/1179555717740130","journal-title":"Clin Med Insights Pathol"},{"issue":"3","key":"3893_CR22","first-page":"6256","volume":"19","author":"N D'Souza","year":"2012","unstructured":"D\u2019Souza N, Loblaw DA, Mamedov A, Sugar L, Holden L (2012) Prostate cancer pathology audits: is central pathology review still warranted? Can J Urol 19(3):6256\u20136260","journal-title":"Can J Urol"},{"key":"3893_CR23","doi-asserted-by":"publisher","unstructured":"Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL (2005) The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on gleason grading of prostatic carcinoma. Am J Surg Pathol 29(9):1228\u20131242. https:\/\/doi.org\/10.1097\/01.pas.0000173646.99337.b1","DOI":"10.1097\/01.pas.0000173646.99337.b1"},{"issue":"2","key":"3893_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1200\/JCO.2010.31.4252","volume":"29","author":"MR Cooperberg","year":"2011","unstructured":"Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, Shinohara K, Meng MV, Greene KL, Carroll PR (2011) Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol 29(2):228\u2013234. https:\/\/doi.org\/10.1200\/JCO.2010.31.4252","journal-title":"J Clin Oncol"},{"issue":"2","key":"3893_CR25","doi-asserted-by":"publisher","first-page":"e425","DOI":"10.1016\/j.clgc.2017.10.007","volume":"16","author":"MJ Whalen","year":"2018","unstructured":"Whalen MJ, Pak JS, Lascano D, Ahlborn D, Matulay JT, McKiernan JM, Benson MC, Wenske S (2018) Oncologic outcomes of definitive treatments for low-and intermediate-risk prostate cancer after a period of active surveillance. Clin Genitourin Cancer 16(2):e425\u2013e435","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"3893_CR26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1113162","volume":"367","author":"TJ Wilt","year":"2012","unstructured":"Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367(3):203\u2013213. https:\/\/doi.org\/10.1056\/NEJMoa1113162","journal-title":"N Engl J Med"},{"issue":"11","key":"3893_CR27","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1111\/j.1464-410X.2012.11434.x","volume":"110","author":"M Bul","year":"2012","unstructured":"Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, Schr\u00f6der FH, Roobol MJ (2012) Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int 110(11):1672\u20131677. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11434.x","journal-title":"BJU Int"},{"issue":"10","key":"3893_CR28","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1311593","volume":"370","author":"A Bill-Axelson","year":"2014","unstructured":"Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, Nordling S, H\u00e4ggman M, Andersson SO, Sp\u00e5ngberg A, Andr\u00e9n O, Palmgren J, Steineck G, Adami HO, Johansson JE (2014) Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 370(10):932\u2013942. https:\/\/doi.org\/10.1056\/NEJMoa1311593","journal-title":"N Engl J Med"},{"issue":"2","key":"3893_CR29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa1615869","volume":"377","author":"TJ Wilt","year":"2017","unstructured":"Wilt TJ, Jones KM, Barry MJ, Andriole GL, Culkin D, Wheeler T, Aronson WJ, Brawer MK (2017) Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med 377(2):132\u2013142. https:\/\/doi.org\/10.1056\/NEJMoa1615869","journal-title":"N Engl J Med"},{"issue":"5","key":"3893_CR30","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.eururo.2016.03.048","volume":"70","author":"RA Godtman","year":"2016","unstructured":"Godtman RA, Holmberg E, Khatami A, Pihl CG, Stranne J, Hugosson J (2016) Long-term results of active surveillance in the g\u00f6teborg randomized, population-based prostate cancer screening trial. Eur Urol 70(5):760\u2013766. https:\/\/doi.org\/10.1016\/j.eururo.2016.03.048","journal-title":"Eur Urol"},{"issue":"5\u20136","key":"3893_CR31","doi-asserted-by":"publisher","first-page":"171","DOI":"10.5489\/cuaj.2806","volume":"9","author":"C Morash","year":"2015","unstructured":"Morash C, Tey R, Agbassi C, Klotz L, McGowan T, Srigley J, Evans A (2015) Active surveillance for the management of localized prostate cancer: Guideline recommendations. Can Urol Assoc J 9(5\u20136):171\u2013178. https:\/\/doi.org\/10.5489\/cuaj.2806","journal-title":"Can Urol Assoc J"},{"issue":"11","key":"3893_CR32","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1097\/pas.0000000000001345","volume":"43","author":"S Sato","year":"2019","unstructured":"Sato S, Kimura T, Yorozu T, Onuma H, Iwatani K, Egawa S, Ikegami M, Takahashi H (2019) Cases having a gleason score 3+4=7 with <5% of gleason pattern 4 in prostate needle biopsy show similar failure-free survival and adverse pathology prevalence to gleason score 6 cases in a radical prostatectomy cohort. Am J Surg Pathol 43(11):1560\u20131565. https:\/\/doi.org\/10.1097\/pas.0000000000001345","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"3893_CR33","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.clgc.2017.10.013","volume":"16","author":"DD Yang","year":"2018","unstructured":"Yang DD, Mahal BA, Muralidhar V, Vastola ME, Boldbaatar N, Labe SA, Nezolosky MD, Orio PF 3rd, King MT, Martin NE, Mouw KW, Trinh QD, Nguyen PL (2018) Pathologic outcomes of gleason 6 favorable intermediate-risk prostate cancer treated with radical prostatectomy: implications for active surveillance. Clin Genitourin Cancer 16(3):226\u2013234. https:\/\/doi.org\/10.1016\/j.clgc.2017.10.013","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"3893_CR34","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/bju.14391","volume":"122","author":"G Gandaglia","year":"2018","unstructured":"Gandaglia G, van den Bergh RCN, Tilki D, Fossati N, Ost P, Surcel CI, Sooriakumaran P, Tsaur I, Valerio M, Kretschmer A, Zaffuto E, Salomon L, Montorsi F, Graefen M, van der Poel H, de la Taille A, Briganti A, Ploussard G (2018) How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator. BJU Int 122(5):823\u2013830. https:\/\/doi.org\/10.1111\/bju.14391","journal-title":"BJU Int"},{"issue":"3","key":"3893_CR35","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.eururo.2016.08.043","volume":"72","author":"A Morlacco","year":"2017","unstructured":"Morlacco A, Cheville JC, Rangel LJ, Gearman DJ, Karnes RJ (2017) Adverse disease features in gleason score 3 + 4 \u201cfavorable intermediate-risk\u201d prostate cancer: implications for active surveillance. Eur Urol 72(3):442\u2013447. https:\/\/doi.org\/10.1016\/j.eururo.2016.08.043","journal-title":"Eur Urol"},{"issue":"13","key":"3893_CR36","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/pros.23040","volume":"75","author":"G Gandaglia","year":"2015","unstructured":"Gandaglia G, Schiffmann J, Schlomm T, Fossati N, Moschini M, Suardi N, Chun FK, Montorsi F, Graefen M, Briganti A (2015) Identification of pathologically favorable disease in intermediate-risk prostate cancer patients: Implications for active surveillance candidates selection. Prostate 75(13):1484\u20131491. https:\/\/doi.org\/10.1002\/pros.23040","journal-title":"Prostate"},{"issue":"2","key":"3893_CR37","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.juro.2018.09.042","volume":"201","author":"S Loeb","year":"2019","unstructured":"Loeb S, Folkvaljon Y, Bratt O, Robinson D, Stattin P (2019) Defining intermediate risk prostate cancer suitable for active surveillance. J Urol 201(2):292\u2013299. https:\/\/doi.org\/10.1016\/j.juro.2018.09.042","journal-title":"J Urol"},{"issue":"3","key":"3893_CR38","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41391-018-0101-6","volume":"22","author":"HL Kim","year":"2019","unstructured":"Kim HL, Li P, Huang HC, Deheshi S, Marti T, Knudsen B, Abou-Ouf H, Alam R, Lotan TL, Lam LLC, du Plessis M, Davicioni E, Fleshner N, Lane BR, Ross AE, Davis JW, Mohler JL, Trock BJ, Klein EA, Tosoian JJ, Hyndman ME, Bismar TA (2019) Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance. Prostate Cancer Prostatic Dis 22(3):399\u2013405. https:\/\/doi.org\/10.1038\/s41391-018-0101-6","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"3893_CR39","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41391-019-0167-9","volume":"23","author":"A Herlemann","year":"2020","unstructured":"Herlemann A, Huang HC, Alam R, Tosoian JJ, Kim HL, Klein EA, Simko JP, Chan JM, Lane BR, Davis JW, Davicioni E, Feng FY, McCue P, Kim H, Den RB, Bismar TA, Carroll PR, Cooperberg MR (2020) Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. Prostate Cancer Prostatic Dis 23(1):136\u2013143. https:\/\/doi.org\/10.1038\/s41391-019-0167-9","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"12","key":"3893_CR40","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1007\/s00330-014-3367-7","volume":"24","author":"T Gondo","year":"2014","unstructured":"Gondo T, Hricak H, Sala E, Zheng J, Moskowitz CS, Bernstein M, Eastham JA, Vargas HA (2014) Multiparametric 3T MRI for the prediction of pathological downgrading after radical prostatectomy in patients with biopsy-proven Gleason score 3 + 4 prostate cancer. Eur Radiol 24(12):3161\u20133170. https:\/\/doi.org\/10.1007\/s00330-014-3367-7","journal-title":"Eur Radiol"},{"issue":"10","key":"3893_CR41","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1007\/s00330-016-4230-9","volume":"26","author":"S Woo","year":"2016","unstructured":"Woo S, Kim SY, Lee J, Kim SH, Cho JY (2016) PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer. Eur Radiol 26(10):3580\u20133587. https:\/\/doi.org\/10.1007\/s00330-016-4230-9","journal-title":"Eur Radiol"},{"key":"3893_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.07.027","author":"E Mazzone","year":"2021","unstructured":"Mazzone E, Gandaglia G, Ploussard G, Marra G, Valerio M, Campi R, Mari A, Minervini A, Serni S, Moschini M (2021) Risk stratification of patients candidate to radical prostatectomy based on clinical and multiparametric magnetic resonance imaging parameters: development and external validation of novel risk groups. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2021.07.027","journal-title":"Eur Urol"},{"issue":"11","key":"3893_CR43","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jclinepi.2004.04.003","volume":"57","author":"PC Austin","year":"2004","unstructured":"Austin PC, Tu JV (2004) Automated variable selection methods for logistic regression produced unstable models for predicting acute myocardial infarction mortality. J Clin Epidemiol 57(11):1138\u20131146. https:\/\/doi.org\/10.1016\/j.jclinepi.2004.04.003","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"3893_CR44","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.eururo.2012.11.005","volume":"63","author":"M Bul","year":"2013","unstructured":"Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, Van Der Schoot DK, Cornel EB, Conti GN (2013) Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 63(4):597\u2013603","journal-title":"Eur Urol"},{"issue":"2","key":"3893_CR45","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.urology.2009.05.050","volume":"75","author":"LF Newcomb","year":"2010","unstructured":"Newcomb LF, Brooks JD, Carroll PR, Feng Z, Gleave ME, Nelson PS, Thompson IM, Lin DW (2010) Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology 75(2):407\u2013413","journal-title":"Urology"},{"issue":"4","key":"3893_CR46","doi-asserted-by":"publisher","first-page":"e0174944","DOI":"10.1371\/journal.pone.0174944","volume":"12","author":"SF Weng","year":"2017","unstructured":"Weng SF, Reps J, Kai J, Garibaldi JM, Qureshi N (2017) Can machine-learning improve cardiovascular risk prediction using routine clinical data? PLoS ONE 12(4):e0174944","journal-title":"PLoS ONE"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-021-03893-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-021-03893-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-021-03893-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T10:09:06Z","timestamp":1643882946000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-021-03893-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["3893"],"URL":"https:\/\/doi.org\/10.1007\/s00345-021-03893-1","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"3 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}